TUEBINGEN, Germany & HOUSTON, Texas–(BUSINESS WIRE)–Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced it has entered into a strategic collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications. The companies will collaborate on the identification, research and development …